身高和体重对输注的凝血因子 VIII C 体内回收率的影响。
Effect of height and weight on the in vivo recovery of transfused factor VIII C.
作者信息
Aronstam A, McLellan D S, Wassef M, Mbatha P S
出版信息
J Clin Pathol. 1982 Mar;35(3):289-91. doi: 10.1136/jcp.35.3.289.
Abstract
The in vivo recovery of factor VIII has been estimated on 84 occasions in 53 severely affected adolescent haemophiliacs. There was wide individual variation in recovery, which was not affected by differences in the administered dose. Recovery increased steadily with increasing surface area, and it was only over a surface area of 1.7 m2 that a recovery of 2% of factor VIII per unit per kg became the norm. It is suggested that the only safe assumption to make below that surface area in an in vivo recovery of 1.5%.
摘要
在53名严重受影响的青少年血友病患者中，已在84个不同场合对凝血因子VIII的体内回收率进行了评估。回收率存在很大的个体差异，且不受给药剂量差异的影响。回收率随着体表面积的增加而稳步上升，只有当体表面积超过1.7平方米时，每千克每单位2%的凝血因子VIII回收率才成为常态。建议在体表面积低于该数值时，唯一安全的假设是体内回收率为1.5%。
相似文献
1
Effect of height and weight on the in vivo recovery of transfused factor VIII C.身高和体重对输注的凝血因子 VIII C 体内回收率的影响。
J Clin Pathol. 1982 Mar;35(3):289-91. doi: 10.1136/jcp.35.3.289.
2
The 'in vivo' survival characteristics of factor VIII procoagulant antigen (VIII:C Ag) in haemophilia A subjects.
Thromb Res. 1982;25(1-2):33-9. doi: 10.1016/0049-3848(82)90212-2.
3
Danazol in Indian haemophiliacs.达那唑在印度血友病患者中的应用
J Assoc Physicians India. 1993 Jan;41(1):23-5.
4
The stability of VIII:C in frozen stored plasma samples--re-examined.冷冻保存血浆样本中Ⅷ因子活性（VIII:C）的稳定性——重新审视
Clin Lab Haematol. 1983;5(2):197-201. doi: 10.1111/j.1365-2257.1983.tb01352.x.
5
Factor VIII procoagulant antigen recovery is a dose-related response to Factor VIII concentrate infusions.凝血因子 VIII 促凝抗原回收率是对凝血因子 VIII 浓缩剂输注的剂量相关反应。
Haemostasis. 1984;14(4):296-301. doi: 10.1159/000215078.
6
Slow thaw siphon technique for cryoprecipitate production.用于冷沉淀生产的缓慢解冻虹吸技术。
Indian J Med Res. 1989 Aug;90:295-9.
7
[Inhibitor hemophilia A--diagnostic and therapeutic significance of controlled substitutions with factor VIII].[抑制性血友病A——凝血因子VIII控制替代治疗的诊断和治疗意义]
Beitr Infusionsther. 1990;26:174-8.
8
[Effect of a single administration of cryoprotein and plasma on factor VIII in hemophilia A].
Vnitr Lek. 1980 Nov;26(11):1101-6.
9
In vitro and in vivo recovery of cryoprecipitated factor 8.冷沉淀因子8的体外和体内回收率
Bibl Haematol. 1970;34:9-17. doi: 10.1159/000384887.
10
Low recovery in vivo of highly purified factor VIII in patients with hemophilia.血友病患者体内高纯度凝血因子VIII的回收率较低。
J Pediatr. 1992 Nov;121(5 Pt 1):814-8. doi: 10.1016/s0022-3476(05)81921-3.
引用本文的文献
1
Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database.根据年龄、血型和浓缩物类型的 FVIII 和 FIX 的半衰期：来自 WAPPS 数据库的数据。
J Thromb Haemost. 2021 Aug;19(8):1896-1906. doi: 10.1111/jth.15395. Epub 2021 Jun 18.
2
Blood volume-based von Willebrand factor to prevent postpartum hemorrhage in von Willebrand disease.基于血容量的血管性血友病因子用于预防血管性血友病患者产后出血
Blood Adv. 2017 Apr 25;1(11):703-706. doi: 10.1182/bloodadvances.2017005090.
3
Progress of in vitro factor VIII coagulant activity from 0 to 8 hours after reconstitution.复溶后0至8小时内体外凝血因子VIII活性的变化情况。
Blood Res. 2014 Dec;49(4):265-9. doi: 10.5045/br.2014.49.4.265. Epub 2014 Dec 23.
4
Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.儿童和成人血浆游离型和白蛋白结合型重组因子 VIII 的比较药代动力学：采血方案对观察到的与年龄相关差异的影响及其对剂量调整的意义。
J Thromb Haemost. 2010 Apr;8(4):730-6. doi: 10.1111/j.1538-7836.2010.03757.x.
5
Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A.3至74岁年龄范围内凝血因子VIII的药代动力学及剂量需求：一项基于50例长期接受血友病A预防性治疗患者的群体分析。
Eur J Clin Pharmacol. 2009 Oct;65(10):989-98. doi: 10.1007/s00228-009-0676-x. Epub 2009 Jun 26.
6
Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.凝血因子的药代动力学：对血友病患者的临床意义
Clin Pharmacokinet. 2001;40(11):815-32. doi: 10.2165/00003088-200140110-00003.
7
Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies.人凝血因子 VIII 的药代动力学。从比较研究中获取临床相关数据。
Clin Pharmacokinet. 1992 May;22(5):385-95. doi: 10.2165/00003088-199222050-00005.
本文引用的文献
1
My student elective. Problems in Peru.我的学生选修课。秘鲁的问题。
Br Med J. 1980 Jan 5;280(6206):32-3. doi: 10.1136/bmj.280.6206.32.
2
Double-blind controlled trial of three dosage regimens in treatment of haemarthroses in haemophilia A.三种给药方案治疗甲型血友病关节积血的双盲对照试验
Lancet. 1980 Jan 26;1(8161):169-71. doi: 10.1016/s0140-6736(80)90659-5.
3
The management of haemophilia.血友病的管理
Practitioner. 1970 Jun;204(224):763-72.
4
The laboratory assessment of the efficacy of antihaemophilic therapy.抗血友病治疗疗效的实验室评估。
S Afr Med J. 1972 Jun 17;46(25):844.
Zotero 插件